Free Health Updates
Skip to main content
Table of Contents
< All Topics
Print

Are U.K Sleep Societies Updating Positions on Cannabis for Sleep Apnoea? 

Posted
Updated
ByMy Patient Advice
Author: Julia Sutton, MSc | Reviewed by: Dr. Clarissa Morton, PharmD

The role of cannabis in obstructive sleep apnoea (OSA)  is increasingly scrutinised, prompting questions about how professional organisations respond. Reviewing UK sleep societies on cannabis provides insight into evolving perspectives. 

Am I eligible for medical cannabis for pain relief?

Current Position 

Most U.K. sleep societies have yet to offer formal endorsements. However, discussions around cannabinoid therapies and emerging research have highlighted a cautious approach. 

Evidence Evaluation 

Sleep society guidance on cannabis focuses on safety, efficacy, and the limited scope of human trials. Professional bodies stress that current evidence is insufficient to recommend routine cannabis use for OSA management. 

Professional Considerations 

Professional bodies on OSA emphasise adherence to established therapies such as CPAP while monitoring ongoing research. Updates from UK sleep societies on cannabis may occur as clinical trial data accumulates, influencing policy and patient recommendations. 

Cautious Optimism 

Despite limited endorsements, sleep society guidance on cannabis acknowledges potential research avenues. Clinicians are advised to balance innovative approaches with existing standards of care to ensure patient safety. 

In summary, UK sleep societies on cannabis remain conservative, reflecting the need for rigorous trials. Professional bodies on OSA continue to monitor evidence, and sleep society guidance on cannabis may evolve as research clarifies safety, dosing, and therapeutic potential for sleep apnoea patients. 

If you’re exploring cannabis treatment options for obstructive sleep apnoea, visit providers like LeafEase for personalised consultations and guidance tailored to your needs. 

For a deeper dive into the science, diagnosis, and full treatment landscape, read our complete guide to Medical Cannabis and Obstructive Sleep Apnoea. 

Julia Sutton, MSc
Author

Julia Sutton is a clinical psychologist with a Master’s in Clinical Psychology and experience providing psychological assessment and therapy to adolescents and adults. Skilled in CBT, client-centered therapy, and evidence-based interventions, she has worked with conditions including depression, anxiety, bipolar disorder, and conversion disorder. She also has experience in child psychology, conducting psycho-educational evaluations and developing tailored treatment plans to improve learning and well-being.

All qualifications and professional experience stated above are authentic and verified by our editorial team. However, pseudonym and image likeness are used to protect the author's privacy. 

Dr. Clarissa Morton, PharmD
Reviewer

Dr. Clarissa Morton is a licensed pharmacist with a Doctor of Pharmacy degree and experience across hospital, community, and industrial pharmacy. She has worked in emergency, outpatient, and inpatient pharmacy settings, providing patient counseling, dispensing medications, and ensuring regulatory compliance. Alongside her pharmacy expertise, she has worked as a Support Plan & Risk Assessment (SPRA) officer and in medical coding, applying knowledge of medical terminology, EMIS, and SystmOne software to deliver accurate, compliant healthcare documentation. Her skills span medication safety, regulatory standards, healthcare data management, and statistical reporting.

All qualifications and professional experience stated above are authentic and verified by our editorial team. However, pseudonym and image likeness are used to protect the reviewers's privacy. 

Categories